Releases
Date
Headline
12 Dec 2018
AC Immune and Lilly Announce License and Collaboration Agreement
07 Dec 2018
In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away
15 Nov 2018
AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission Tomography (PET) Tracer for Parkinson's Disease
13 Nov 2018
AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update
12 Nov 2018
AC Immune to Present at the Jefferies 2018 London Healthcare Conference
09 Nov 2018
AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases
01 Nov 2018
AC Immune to Present at 2018 Society for Neurosciences Meeting
01 Nov 2018
AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases
29 Oct 2018
AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620
29 Oct 2018
AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy
25 Oct 2018
AC Immune Selected to Present Progress on its Tau Morphomer Program in the Late Breaking News Session at CTAD Conference in Barcelona
22 Oct 2018
AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence
20 Aug 2018
AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome
08 Aug 2018
AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update
31 Jul 2018
AC Immune Announces Successful Closing of Second Subscription Rights Offering
25 Jul 2018
New Phase 2 Data Analysis for Crenezumab Presented at Global Alzheimer's Conference Provides Strong Evidence for Engagement of the Principle Abeta Target
24 Jul 2018
AC Immune Announces Closing of First Subscription Rights Offering and Primary Offering as well as Full Exercise of Option to Purchase Additional Shares
19 Jul 2018
AC Immune Announces Price of USD 11.75 for Offerings and Issuance of up to 10 Million Common Shares
17 Jul 2018
AC Immune Announces Offerings and Issuance of up to 10 Million Common Shares
17 Jul 2018
Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Technology Platforms to be presented at AAIC in Chicago
06 Jul 2018
AC Immune Announces Results of Annual General Meeting
02 May 2018
AC Immune Reports First Quarter 2018 Financial Results and Corporate Update
27 Apr 2018
AC Immune Announces Results of Extraordinary Shareholders Meeting
05 Apr 2018
AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease
20 Mar 2018
AC Immune reports full-year 2017 financial results - successful first year as a public company
15 Mar 2018
AC Immune prepares for a first in human study of a promising positron emission tomography (PET) tracer for Parkinson's disease
06 Feb 2018
AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference
Date
Headline
01 Dec 2017
AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases
21 Nov 2017
AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases
13 Nov 2017
AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update
02 Nov 2017
AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease
24 Oct 2017
AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference
03 Oct 2017
AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinson's Research
12 Sep 2017
AC IMMUNE COMPLETES RECRUITMENT FOR LOW-DOSE COHORT IN WORLD'S FIRST CLINICAL TRIAL FOR ANTI-ABETA VACCINE TARGETING ALZHEIMER'S DISEASE-LIKE CHARACTERISTICS IN INDIVIDUALS WITH DOWN SYNDROME
22 Aug 2017
AC IMMUNE DISCOVERS NEXT-GENERATION ANTIBODIES FOCUSED ON NEURODEGENERATIVE DISEASES
09 Aug 2017
AC IMMUNE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS
10 Jul 2017
AC IMMUNE PROVIDES SEVEN UPDATES ON ITS PIPELINE AND TECHNOLOGY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
28 Jun 2017
AC IMMUNE ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING
22 May 2017
AC IMMUNE AND ESSEX BIO-TECHNOLOGY ANNOUNCE RESEARCH COLLABORATION FOR NEURODEGENERATIVE DISEASES AND NEUROINFLAMMATION
11 May 2017
AC IMMUNE SA REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS
03 Apr 2017
Piramal Imaging and AC Immune present first clinical data for tau PET-imaging tracer at International Alzheimer's Conference
23 Mar 2017
AC IMMUNE PROVIDES TWELVE UPDATES ON ITS PIPELINE AT THE INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES
17 Mar 2017
AC IMMUNE REPORTS FULL YEAR 2016 FINANCIAL RESULTS AND R&D UPDATE
28 Feb 2017
AC IMMUNE PARTNER GENENTECH TO START SECOND PHASE 3 CLINICAL TRIAL FOR ALZHEIMER'S THERAPY CRENEZUMAB
Date
Headline
09 Dec 2016
AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB
23 Nov 2016
AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER
15 Nov 2016
AC Immune SA announces results of annual general meeting
11 Nov 2016
AC Immune SA Reports Third Quarter 2016 Results
23 Sep 2016
Switzerland's AC Immune Opens For Trading On NASDAQ
23 Sep 2016
AC Immune SA Announces Pricing of Upsized Initial Public Offering
13 Sep 2016
AC Immune SA Commences Proposed Initial Public Offering of Common Shares
07 Jul 2016
AC Immune to receive milestone payment for Anti-Tau Antibody moving into Phase 1 trial for Alzheimer's disease
09 May 2016
AC Immune raises USD 43.5 million (CHF 42.7 million) in financing round E
18 Apr 2016
AC Immune announces a research and development collaboration in neurodegenerative diseases with Biogen
05 Apr 2016
AC Immune announces publication of ground-breaking scientific publication on anti-Abeta vaccine in preclinical model of Down syndrome
07 Jan 2016
World's first clinical trial for anti-Abeta vaccine targeting Alzheimer's disease-like characteristics in people with Down syndrome
Date
Headline
23 Sep 2015
AC Immune signs collaboration agreement with Nestlé Institute of Health Sciences to develop Alzheimer's disease diagnostic
22 Jul 2015
AC Immune receives milestone payment for crenezumab moving into phase III clinical development in Alzheimer's disease
13 Jul 2015
AC Immune receives milestone in Anti-Tau Antibody collaboration with Genentech
12 Feb 2015
AC Immune Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research
12 Jan 2015
AC Immune Enters into a Worldwide License and Collaboration Agreement for Alzheimer's Disease Therapeutic anti-Tau Vaccines with Janssen Pharmaceuticals, Inc.
Date
Headline
16 Jul 2014
Crenezumab Phase II cognition data in Alzheimer's disease presented
16 Jul 2014
Crenezumab Phase II cognition data in Alzheimer's disease presented
12 May 2014
AC Immune and Piramal Imaging announce out-licensing agreement for the development of Tau protein diagnostics in Alzheimer's disease
12 May 2014
AC Immune and Piramal Imaging announce out-licensing agreement for the development of Tau protein diagnostics in Alzheimer's disease
09 Jan 2014
AC Immune raises CHF 20 million and initiates world's first anti-pTau vaccine trial for Alzheimer's disease
23 Dec 2013
Alzheimer's Prevention Initiative (API) Trial marks milestone
31 Jan 2013
AC Immune to discontinue development of ACI-91 small molecule
11 Dec 2012
FierceBiotech & Recognition of Prof. Pfeifer's personal qualities
19 Sep 2012
AC Immune Named One of "Fierce 15" Leading Biotech Companies of 2012
18 Jun 2012
AC Immune and Genentech Enter into Second Antibody Collaboration for Alzheimer's Disease
16 May 2012
AC Immune Therapy chosen for groundbreaking Alzheimer's Disease Trial in Colombia and USA
17 Jan 2012
Development of new medicines for memory impairment
09 May 2011
AC Immune recieves significant milestone payment from Genentech
31 May 2010
Prof. Andrea Pfeifer represents Switzerland at the election of the Ernst & Young World Entrepreneur Of Year
14 Jan 2010
AC Immune boosts its preclinical Alzheimer's pipeline
24 Oct 2009
Prof. Andrea Pfeifer - CEO of AC Immune - awarded Swiss Life Science/High-Tech Entrepreneur of the Year 2009
08 Oct 2009
AC Immune and Bayer Schering Pharma collaborate in brain imaging for Alzheimer's Disease
26 Jan 2009
AC Immune Shapes its Future as World Economic Forum Technology Pioneer 2009
04 Dec 2008
Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development
07 Dec 2006
Genentech and AC Immune: Exclusive License Agreement
11 May 2005
AC Immune raises CHF 21 million in private financing round